Scientific Advisory Board Members
Prof. Esther H. Chang, MD, PhD
Professor Esther H. Chang is a member of the Departments of Oncology and Otolaryngology at the Lombardi Cancer Center, Georgetown University Medical Center. Before joining Georgetown University, Dr. Chang held positions in the National Cancer Institute, as a professor in the Department of Surgery at Stanford University, and as a professor in the Departments of Pathology and Surgery at the Uniformed Services University of the Health Sciences. Dr. Chang has been a pioneer and major contributor to understanding genetic influences on both the development and suppression of cancerous tumors, as well as to understanding the tumor’s resistance to radio/chemotherapy. She was the first to identify human versions of a mouse viral oncogene and to demonstrate the role of these “ras oncogenes” in causing cancer. Her research group also was the first to demonstrate, simultaneously with another, that a mutated p53 gene inherited in a cancer-prone family plays a role in the early stages of cancer development.
Recently, her research on the application of nanotechnology to cancer therapy, diagnosis and prevention was recognized in Science News Magazine as among the most promising efforts in the field. Her group also has been evaluating the combination of tumor-targeted gene therapy and more conventional radiotherapy or chemotherapy for treatment of cancers.
Dr. Chang has served as a member of a number of scientific advisory boards for the National Cancer Institute, NASA, the US Military Cancer Institute, and the Department of Energy. Her scientific findings have been published in prominent journals including Nature, Science, and Cell, as well as many other leading journals. Dr. Chang also has dedicated much time to the education of graduate and medical students, and has held peer reviewed grants from the NIH for more than 20 years, without interruption.